Vaxcyte Corporate Presentation

12 Vaxcyte PCV Franchise Designed to Offer Broader Protection Potential for Sustained Leadership in the Established >$7B Pneumococcal Vaccine Market VAX-24: Category-leading 24-valent PCV incorporating carrier-sparing conjugates о VAX-XP: Next-generation >30-valent PCV showcases franchise approach and scalability of carrier-sparing conjugates 6B 9V 14 18C 19F 23F 1 5 7F 3 6A 19A 33F 22F 8 10A 11A 12F 15B 2 9N 17F 20 A B C D Prevnar Synflorix Prevnar 13 Madaga More Vaxneuvance" Pneumococcal 15-valent Prevnar 20™ Pneumococcal 20-valent Conjugate Vaccine PNEUMOVAX23 VAX-24 VAX-XP Source: Prescribing information for Prevnar, Prevnar 13, Prevnar20, Synflorix, Vaxneuvance, and Prevnar 20. Company filings for Vaxcyte LU E LL F G H | J TBD Spectrum of Coverage Drives Adoption

View entire presentation